Mirova Has $7.15 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mirova grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,703 shares of the medical equipment provider’s stock after purchasing an additional 486 shares during the quarter. Intuitive Surgical comprises 1.2% of Mirova’s portfolio, making the stock its 17th biggest holding. Mirova’s holdings in Intuitive Surgical were worth $7,152,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ISRG. Atala Financial Inc bought a new position in Intuitive Surgical in the 4th quarter worth approximately $25,000. Hurley Capital LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $28,000. Berbice Capital Management LLC bought a new position in Intuitive Surgical during the fourth quarter worth $26,000. BankPlus Trust Department acquired a new position in Intuitive Surgical during the 4th quarter valued at $28,000. Finally, Summit Securities Group LLC acquired a new position in Intuitive Surgical during the 4th quarter valued at $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Brian Edward Miller sold 8,900 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the sale, the executive vice president now owns 5,758 shares in the company, valued at approximately $2,793,033.06. This represents a 60.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,754 shares of company stock valued at $17,691,621. 0.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on ISRG. Bernstein Bank upped their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Evercore ISI upped their price target on Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. UBS Group lifted their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Citigroup lifted their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Finally, CICC Research assumed coverage on shares of Intuitive Surgical in a report on Monday, January 27th. They set a “neutral” rating and a $550.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $611.81.

Intuitive Surgical Stock Up 0.3 %

Shares of ISRG opened at $482.74 on Friday. The firm has a market capitalization of $171.94 billion, a PE ratio of 75.31, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. Intuitive Surgical, Inc. has a 12-month low of $364.31 and a 12-month high of $616.00. The stock’s fifty day simple moving average is $522.23 and its 200-day simple moving average is $532.34.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.